TICKERNERD
Menu
FBIOFBIOHealthcare · Biotechnology

FBIO Stock Forecast: Fortress Biotech, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$2.87
+3.43% on the day

The 2 Wall Street analysts covering Fortress Biotech, Inc. hold a median 12-month price target of $11 — +283.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 78 of 100 as at 21 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$95.1M
Ticker Nerd rank
78 / 100
Median analyst target
$11
Analysts covering
2
Total return, dividends reinvested
1W
−2.2%
1M
−18.8%
YTD
−21.7%
1Y
+27.9%
From 52W high
−34.6%
From 52W low
+29.1%
$2.22
$4.38
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

FBIO stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Fortress Biotech, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Aug 2026
78 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
94
Growth
92
Size
76
Momentum
64
Issuance
61
Volatility
60
Revisions
52
Accruals
41
Value
28

Quality (94): The business earns solid, repeatable profits on what it owns.

Value (28): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

FBIO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on FBIO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00Oct 25Jan 26Apr 26Jul 26FBIOHigh $17Median $11Low $5

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says2 analysts
2 Buy0 Hold0 Sell
Low $5Median $11High $17

The green dot is the last close — the median target sits +283.9% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 4 moved it down.

DateFirmActionRatingTarget
23 Feb 2026HC Wainwright & Co.ReiteratesBuy$17
21 Aug 2025HC Wainwright & Co.MaintainsBuy—
11 Mar 2025Roth MKMReiteratesBuy—
18 Nov 2024HC Wainwright & Co.MaintainsBuy—
19 July 2024HC Wainwright & Co.ReiteratesBuy—
20 June 2024Cantor FitzgeraldReiteratesOverweight—
16 May 2024Roth MKMReiteratesBuy—
19 Mar 2024Alliance Global PartnersInitiatesBuy—
15 Mar 2024Roth MKMReinstatesBuy$10
29 Nov 2023Roth MKMMaintainsBuy—
15 Aug 2023Cantor FitzgeraldReiteratesOverweight$5.00
16 May 2023Cantor FitzgeraldMaintainsOverweight$6.00 → $5.00
6 Apr 2023BenchmarkReiteratesSpeculative Buy$5.00
4 Aug 2022Ladenburg ThalmannInitiatesBuy$6.00
14 July 2022B. Riley SecuritiesMaintainsBuy$8.00 → $6.00
20 Apr 2021Roth CapitalMaintainsBuy$4.50 → $5.00
13 Oct 2020Roth CapitalMaintainsBuy$5.00 → $4.75
12 Oct 2020HC Wainwright & Co.MaintainsBuy$11 → $10
2 Oct 2020BenchmarkInitiatesBuy—
13 Mar 2020B. Riley FBRMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. FBIO appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

FBIO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Fortress Biotech, Inc. (FBIO) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
1.0×

Cheaper than 71% of US stocks

Price / sales
1.3×

Cheaper than 63% of US stocks

Price / book
0.6×

Cheaper than 84% of US stocks

EV / EBITDA
0.3×

Cheaper than 59% of US stocks

Growth & margins
Revenue growth (YoY)
14.0%

Higher than 61% of US stocks

Earnings growth (YoY)
22.1%

Higher than 61% of US stocks

Gross margin
61.2%

Higher than 75% of US stocks

Operating margin
−53.5%

Higher than 16% of US stocks

Net margin
163.3%

Higher than 99% of US stocks

Returns & dividend
Return on equity
116.0%

Higher than 97% of US stocks

Return on assets
−7.7%

Higher than 28% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

FBIO vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
FBIOFortress Biotech, Inc.$95.1M
78
CGTXCognition Therapeutics, Inc.$94.7M
39
ACRVAcrivon Therapeutics, Inc.$94.6M
68
BMEABiomea Fusion, Inc.$96.9M
50
YARWYarrow Bioscience, Inc.$97.2M
51
PYPDPolyPid Ltd.$97.3M
50
ATRAAtara Biotherapeutics, Inc.$97.4M
66

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Fortress Biotech, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest FBIO news & analysis

Fortress Biotech Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

GlobeNewsWire · 13 Aug 2026positive

Fortress Biotech reported second quarter 2026 financial results, with total net revenue rising 14% to $18.7 million compared to the same period in 2025. The company also highlighted advancements in its partnered programs, including Crystalys Therapeutics' $130 million Series B financing to support dotinurad development and royalties from the launches of ZYCUBO and UNLOXCYT.

Why it matters — The 14% revenue increase, Series B financing for a partnered program, and new product royalties signal progress across Fortress's revenue and partnered-program activities in the latest quarter.

Fortress Biotech, Inc. (FBIO) Q2 2026 Earnings Call Transcript

Seeking Alpha · 13 Aug 2026neutral

A transcript of Fortress Biotech, Inc.'s Q2 2026 earnings call was published on Seeking Alpha, based on the company's second-quarter 2026 earnings conference. The item provides a record of the company's earnings call discussion.

Why it matters — FBIO watchers would care because the earnings call transcript offers insight into management's commentary on the company's latest quarterly results.

Fortress Biotech Q2 Earnings Call Highlights

MarketBeat · 12 Aug 2026positive

On its second-quarter earnings call, Fortress Biotech highlighted that subsidiary Journey Medical reported higher revenue and improved profitability, driven by continued prescription growth and better payer reimbursement for its rosacea treatment Emrosi.

Why it matters — For Fortress Biotech watchers, Journey Medical's stronger performance signals improving commercial traction for a key subsidiary's lead product.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duties by Certain Officers and Directors of Fortress Biotech, Inc. (NASDAQ: FBIO)

PRNewsWire · 7 Aug 2026negative

Levi & Korsinsky, LLP has announced an investigation into Fortress Biotech, Inc. concerning possible breaches of fiduciary duties by certain officers and directors. The law firm is currently seeking information from FBIO shareholders.

Why it matters — The investigation raises questions about potential misconduct by FBIO leadership, which could lead to legal or regulatory consequences for the company.

FAQ

Frequently asked questions about FBIO stock

What is the FBIO stock price forecast for 2026-2027?

The 2 Wall Street analysts covering Fortress Biotech, Inc. have a median 12-month price target of $11, with estimates ranging from $5 to $17. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is FBIO stock a buy right now?

Of the 2 analysts covering Fortress Biotech, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Fortress Biotech, Inc. 78 out of 100 across roughly 4,600 US stocks as at 21 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank FBIO?

As at 21 Aug 2026, Fortress Biotech, Inc. ranks 78 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (94 of 100).

Will FBIO stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +283.9% from the last close, and Ticker Nerd's factor model ranks Fortress Biotech, Inc. 78 out of 100 as at 21 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the FBIO stock forecast for 2030?

No analyst covering Fortress Biotech, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for FBIO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $17 over the next 12 months.

How has FBIO stock performed over the past year?

Fortress Biotech, Inc. returned +27.9% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Fortress Biotech, Inc. do?

Fortress Biotech Inc. operates as a biopharmaceutical company involved in the development and commercialization of novel pharmaceutical and biotechnology products.

What is the latest news on FBIO?

The most recent item we track (GlobeNewsWire, 13 Aug 2026): "Fortress Biotech Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights". Fortress Biotech reported second quarter 2026 financial results, with total net revenue rising 14% to $18.7 million compared to the same period in 2025. The company also highlighted advancements in its partnered programs, including Crystalys Therapeutics' $130 million Series B financing to support dotinurad development and royalties from the launches of ZYCUBO and UNLOXCYT.

Company

About Fortress Biotech, Inc.

Fortress Biotech Inc. operates as a biopharmaceutical company involved in the development and commercialization of novel pharmaceutical and biotechnology products. Its primary function is to nurture and advance a diverse portfolio of potential new treatments for rare diseases, cancer, and other serious health conditions. A distinctive feature of Fortress Biotech is its innovative partnership model; it acquires, develops, and commercializes these therapies through multiple subsidiary companies and licensing agreements. This structure allows for specialized focus and flexibility in progressing early-stage drug candidates. Fortress Biotech significantly impacts the healthcare sector, particularly in areas of unmet medical needs where it seeks to bring breakthrough therapies to market. By creating a platform for research and development across its subsidiaries, the company plays a crucial role in fostering advancements in medical treatments and addressing critical gaps within pharmaceutical innovation and patient care.

CEO Dr. Lindsay Allan Rosenwald M.D. · 78 employees · United States · https://www.fortressbiotech.com